What it sells
Growing micro-organs to find new drugs
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma/biotech partners and funders (site has a Partnership section); rare-disease families supply patient mutations. Analyst inference.
Workflow: what inputs become what output?
Model human development with organoids carrying the same gene mutation as the child, then screen drugs in those models to find therapies for rare genetic diseases.
Economics: what it saves and how it charges
Early-stage therapy developer; no revenue model stated. Site cites that only 5% of rare diseases have approved treatments.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.